Neurology
-
Randomized Controlled Trial Multicenter Study
Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
To determine whether droxidopa, an oral norepinephrine precursor, improves symptomatic neurogenic orthostatic hypotension (nOH). ⋯ This study provides Class I evidence that in patients with symptomatic nOH who respond to open-label droxidopa, droxidopa improves subjective and objective manifestation of nOH at 7 days.